OTCMKTS:PMCBD PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis $6.68 -0.96 (-12.54%) As of 11/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About PharmaCyte Biotech Stock (OTCMKTS:PMCBD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PharmaCyte Biotech alerts:Sign Up Key Stats Today's Range$6.50▼$8.1750-Day Range$0.30▼$0.4952-Week Range$5.56▼$55.50Volume126,655 shsAverage Volume8,831 shsMarket Capitalization$11.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s primary program has centered on locally advanced pancreatic cancer, an aggressive disease with limited treatment options. PharmaCyte’s investigational approach uses its Cell-in-a-Box technology, which involves encapsulating genetically engineered cells in proprietary cellulose-based capsules. These cells are designed to produce an enzyme that converts the chemotherapy prodrug ifosfamide into its active form near the tumor, with the goal of concentrating treatment at the disease site while reducing exposure to healthy tissue. PharmaCyte Biotech does not have commercially marketed products and has focused primarily on research, clinical development, regulatory activities and potential partnerships. The company’s programs have been developed for international clinical and regulatory markets, although their availability remains dependent on successful clinical trials and regulatory approval.AI Generated. May Contain Errors. Read More Receive PMCBD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMCBD Stock News HeadlinesPharmaCyte Biotech Reports Strong Cash and Asset PositionNovember 13 at 12:19 PM | finance.yahoo.comPharmaCyte Biotech, Inc. Announces Reverse Stock SplitNovember 11, 2026 | finance.yahoo.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 15 at 1:00 AM | Behind the Markets (Ad)PharmaCyte Biotech Inc.May 14, 2026 | barrons.comHedge Fund and Insider Trading News: Paul Singer, Steve Cohen, Israel Englander, Ray Dalio, Rokos Capital Management, Viking Global, PharmaCyte Biotech Inc (PMCB), Cloudflare Inc (NET), and MoreJanuary 9, 2026 | insidermonkey.comPharmaCyte sells Femasys stake, sees cash position rising to $20MNovember 25, 2025 | msn.comPharmaCyte Biotech stock surges following profitable exit from Femasys investmentNovember 25, 2025 | msn.comPharmaCyte Biotech Amends Equity Incentive PlanOctober 31, 2025 | msn.comSee More Headlines PMCBD Stock Analysis - Frequently Asked Questions How have PMCBD shares performed this year? PharmaCyte Biotech's stock was trading at $0.7101 at the start of the year. Since then, PMCBD stock has increased by 840.7% and is now trading at $6.68. How do I buy shares of PharmaCyte Biotech? Shares of PMCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:PMCBD CIKN/A Webwww.pharmacyte.com Phone(917) 595-2850FaxN/AEmployeesN/AYear Founded1996Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.09% Return on Assets-43.39% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,671,000Free FloatN/AMarket Cap$11.16 million OptionableNot Optionable Beta0.27 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (OTCMKTS:PMCBD) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.